Search
Close this search box.

Fairness Opinion: De-SPAC Transaction for Private Biotech Company

SPAC Seeks Independent Valuation of Target in Mental Health Disorders

Background

A special purpose acquisition company (SPAC) was contemplating entering into a Business Combination Agreement with a private biotechnology company working to develop psilocybin products, medical formulations and related protocols to treat mental health disorders in a clinical environment.  The SPAC retained RNA to render an opinion as to whether the target company’s implied valuation in the transaction would be fair, from a financial point of view, to the SPAC.

Approach

Performed extensive due diligence, including conducting multiple interviews with the target company’s management team and assessing pricing/reimbursement issues.

Valued the target company using the income approach by analyzing the company’s lead program for both its primary and secondary indication.

Valued the target company using the market approach by considering private company financing transactions.

Outcomes

RNA presented its findings to the SPAC’s Board of Directors and rendered a written opinion which concluded that the target company’s implied valuation in the transaction was fair was fair, from a financial point of view, to the SPAC.

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.